Hezheng Pharmaceutical has formed a global partnership for targeted protein degradation drug licensing with a U.S. biotechnology company, marking a significant milestone in China's biopharmaceutical industry.

Target Information

Hezheng Pharmaceutical, founded in July 2012, is an innovative biotechnology company focused on the research and development of small-molecule drugs. The company operates at the clinical stage and aims to address unmet clinical needs through advanced technology. Hezheng has developed a unique platform for targeted protein degradation (TPD) and intelligent drug development, concentrating its efforts on the treatment of diseases such as cancer, autoimmune disorders, and central nervous system conditions. Currently, the company has over 10 projects in its pipeline related to first-in-class drugs, with six molecules actively in clinical research and two approaching critical registration trials. One of these molecules has even received breakthrough therapy designation.

Hezheng's impressive track record includes establishing six collaborations for new drug development with renowned pharmaceutical companies, such as Johnson & Johnson. These partnerships demonstrate the industry’s recognition of Hezheng’s capabilities and potential in drug discovery.

Industry Overview in China

The biopharmaceutical industry in China is rapidly evolving, bolstered by significant investments and government support for innovation in drug development. In recent years, China has positioned itself as a key player in the global biopharmaceutical market, with fir